Hans Garmo

17.2k total citations · 4 hit papers
298 papers, 11.5k citations indexed

About

Hans Garmo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Hans Garmo has authored 298 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Pulmonary and Respiratory Medicine, 99 papers in Oncology and 78 papers in Cancer Research. Recurrent topics in Hans Garmo's work include Prostate Cancer Treatment and Research (118 papers), Prostate Cancer Diagnosis and Treatment (98 papers) and Cancer, Lipids, and Metabolism (43 papers). Hans Garmo is often cited by papers focused on Prostate Cancer Treatment and Research (118 papers), Prostate Cancer Diagnosis and Treatment (98 papers) and Cancer, Lipids, and Metabolism (43 papers). Hans Garmo collaborates with scholars based in Sweden, United Kingdom and United States. Hans Garmo's co-authors include Lars Holmberg, Pär Stattin, Anna Bill‐Axelson, Mieke Van Hemelrijck, Mats Lambe, Hans‐Olov Adami, Jan Adolfsson, Jan‐Erik Johansson, Stig Nordling and Michael Häggman and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Hans Garmo

288 papers receiving 11.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer

2005 794 citations Anna Bill‐Axelson, Lars Holmberg et al. New England Journal of Medicine profile →
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer

2011 778 citations Anna Bill‐Axelson, Lars Holmberg et al. New England Journal of Medicine profile →
Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer

2014 643 citations Anna Bill‐Axelson, Lars Holmberg et al. New England Journal of Medicine profile →
Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-up

2018 284 citations Anna Bill‐Axelson, Lars Holmberg et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Hans Garmo

Since Specialization

Citations

This map shows the geographic impact of Hans Garmo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Garmo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Garmo more than expected).

Fields of papers citing papers by Hans Garmo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Garmo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Garmo. The network helps show where Hans Garmo may publish in the future.

Co-authorship network of co-authors of Hans Garmo

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Garmo. A scholar is included among the top collaborators of Hans Garmo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Garmo. Hans Garmo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discriminative Ability of the Charlson Comorbidity Index for Long-Term Mortality in a General Population: Nationwide, Population-Based Study of 10 Million Adults in Sweden 2025 ·Clinical Epidemiology ·Marcus Westerberg, Hans Garmo, Jonas F. Ludvigsson, P. Stattin, Rolf Gedeborg	0
2	Gleason scores provide more accurate prognostic information than grade groups 2025 ·Pathology ·Lars Egevad, (unknown), Brett Delahunt, Hemamali Samaratunga, Hans Garmo, Pär Stattin, Martin Eklund	2
3	Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study 2024 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Lars Egevad, (unknown), Brett Delahunt, Hemamali Samaratunga, (unknown), Hans Garmo, Pär Stattin, Martin Eklund	2
4	Population‐based study of disease trajectory after radical treatment for high‐risk prostate cancer 2024 ·British Journal of Urology ·Pär Stattin, (unknown), Xiwu Lin, Florence Lefresne, Sabine Brookman‐May, Suneel Mundle, (unknown), Dina Gifkins, David Robinson, Johan Styrke, Hans Garmo	0
5	Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case–control study 2024 ·British journal of surgery ·(unknown), (unknown), Balázs Ács, Johan Hartman, Irma Fredriksson, Hans Garmo, Fredrik Wärnberg, Malin Sund	2
6	Temporal trend in risk of prostate cancer death in men with favourable-risk prostate cancer 2024 ·Scandinavian Journal of Urology ·Frederik Birkebæk Thomsen, Hans Garmo, Lars Egevad, Pär Stattin, Klaus Brasso	0
7	Patient-reported Side Effects 1 Year After Radical Prostatectomy or Radiotherapy for Prostate Cancer: A Register-based Nationwide Study 2024 ·European Urology Oncology ·Christian Corsini, Oskar Bergengren, Stefan Carlsson, Hans Garmo, (unknown), Per-Anders Fransson, Jon Kindblom, David Robinson, Marcus Westerberg, Pär Stattin, (unknown), (unknown)	14
8	Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy 2023 ·JAMA Network Open ·Christian Corsini, Hans Garmo, (unknown), Rolf Gedeborg, Pär Stattin, Marcus Westerberg	17
9	Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden 2022 ·BMJ Open ·Yanina Balabanova, (unknown), Hans Garmo, Pär Stattin, Gunnar Brobert	3
10	Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study 2021 ·The Breast ·(unknown), Miguel Garcia‐Argibay, Hans Garmo, Johan Ahlgren, Anna-Karin Wennstig, Irma Fredriksson, Henrik Lindman, Antonios Valachis	28
11	Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998–2016 2020 ·Acta Oncologica ·Kerri Beckmann, Hans Garmo, Per Nilsson, Ingela Franck Lissbrant, Anders Widmark, Pär Stattin	10
12	Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-up breakdown → 2018 ·New England Journal of Medicine ·Anna Bill‐Axelson, Lars Holmberg, Hans Garmo, Kimmo Taari, Christer Busch, Stig Nordling, Michael Häggman, Swen‐Olof Andersson, Ove Andrén, Gunnar Steineck, Hans‐Olov Adami, Jan‐Erik Johansson	284
13	Androgen deprivation therapy for prostate cancer and risk of dementia 2018 ·European Urology Supplements ·David S. Robinson, Hans Garmo, Mieke Van Hemelrijck, J.‐E. Damber, Ola Bratt, (unknown), Lars‐Olof Wahlund, P. Stattin, Jan Adolfsson	5
14	A latent class model for competing risks 2017 ·Statistics in Medicine ·M. Rowley, Hans Garmo, Mieke Van Hemelrijck, Wahyu Wulaningsih, Birgitta Grundmark, Björn Zethelius, Niklas Hammar, (unknown), Masato Inoue, Lars Holmberg, A C C Coolen	10
15	Serum inflammatory markers and colorectal cancer risk and survival 2017 ·British Journal of Cancer ·(unknown), Mieke Van Hemelrijck, Hans Garmo, Lars Holmberg, Håkan Malmström, Mats Lambe, Niklas Hammar, Göran Walldius, Ingmar Jungner, Wahyu Wulaningsih	62
16	Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe) 2017 ·BMJ Open ·Christel Häggström, Fredrik Liedberg, Oskar Hagberg, Firas Aljabery, Viveka Ströck, Abolfazl Hosseini, Truls Gårdmark, Amir Sherif, Per‐Uno Malmström, Hans Garmo, Staffan Jahnson, Lars Holmberg	40
17	Rate Of Malignant Transformation In High Risk Et During 5 Years Of Follow-Up Of Cytoreductive Therapy 2016 ·Haematologica ·Gunnar Birgegård, Yasin Folkvaljon, Hans Garmo, Carlos Besses, Martin Grießhammer, L Gugliotta, Claire Harrison, (unknown), Joseph Wu, (unknown), Jean‐Jacques Kiladjian	1
18	Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma 2015 ·JAMA ·Stacy Loeb, Yasin Folkvaljon, Mats Lambe, David Robinson, Hans Garmo, Christian Ingvar, Pär Stattin	66
19	Primary cancers before and after prostate cancer diagnosis 2012 ·Cancer ·Mieke Van Hemelrijck, Linda Drevin, Lars Holmberg, Hans Garmo, Jan Adolfsson, Pär Stattin	23
20	Biomarker-based score to predict mortality in persons aged 50 years and older: a new approach in the Swedish AMORIS study. 2012 ·Research Portal (King's College London) ·Mieke Van Hemelrijck, Danielle Harari, Hans Garmo, Niklas Hammar, Göran Walldius, Mats Lambe, Ingmar Jungner, Lars Holmberg	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact